Advertisement
U.S. markets open in 2 hours 5 minutes

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.04-0.45 (-6.01%)
At close: 04:00PM EDT
7.28 +0.24 (+3.41%)
Pre-Market: 07:25AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close7.49
Open7.49
Bid7.96 x 1300
Ask8.50 x 1100
Day's Range6.95 - 7.50
52 Week Range1.63 - 8.83
Volume2,264,860
Avg. Volume2,876,265
Market Cap698.632M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FATE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fate Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $

  • Insider Monkey

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript February 26, 2024 Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Fate […]

  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming March Investor Conferences

    SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen’s 44th Annual Health Care Conference on Wednesday, Mar